---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022428"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-05-12T13:20:15+00:00"
generated_at: "2026-05-12T13:21:15.154532+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "medium"
source: SEC EDGAR
---

# bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025

## Summary
- Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.
- Sales growth so far in 2026 exceeds internal projections, reflecting accelerating physician adoption.
- CyPath Lung uses flow cytometry + AI for noninvasive lung cancer detection; 92% sensitivity, 87% specificity in trial.
- Company advancing longitudinal clinical study, expanding use for lung cancer survivor monitoring, and R&D pipeline for asthma/COPD.
- CEO Maria Zannes highlights CyPath Lung's role in risk stratification and nodule management.

## SEC filing metadata
- accession: 0001493152-26-022428
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-05-12T13:20:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226022428/0001493152-26-022428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226022428/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022428
- JSON: https://secwatch.observer/filing/0001493152-26-022428.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.